Vical hails universal vaccine adjuvant in research review
Vical has published a review of Vaxfectin data showing the adjuvant boosts the immune response of DNA-based vaccines against cancer and a range of pathogens.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs